Wall Street analysts expect Insulet Corporation (NASDAQ:PODD) to post $114.24 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Insulet Corporation’s earnings. The highest sales estimate is $117.44 million and the lowest is $108.70 million. Insulet Corporation posted sales of $94.87 million during the same quarter last year, which suggests a positive year over year growth rate of 20.4%. The company is expected to announce its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Insulet Corporation will report full year sales of $114.24 million for the current financial year, with estimates ranging from $433.00 million to $454.09 million. For the next financial year, analysts forecast that the firm will report sales of $536.65 million per share, with estimates ranging from $504.90 million to $571.17 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Insulet Corporation.

Insulet Corporation (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The firm had revenue of $110 million for the quarter, compared to analysts’ expectations of $106.23 million. During the same period last year, the firm earned ($0.08) earnings per share. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year.

A number of research analysts recently issued reports on PODD shares. Jefferies Group LLC reaffirmed a “buy” rating on shares of Insulet Corporation in a report on Friday, June 16th. BidaskClub raised Insulet Corporation from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 27th. Canaccord Genuity reaffirmed a “hold” rating and set a $42.00 target price on shares of Insulet Corporation in a report on Friday, May 26th. Cowen and Company reaffirmed a “buy” rating and set a $52.00 target price on shares of Insulet Corporation in a report on Friday, July 14th. Finally, ValuEngine raised Insulet Corporation from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Insulet Corporation has a consensus rating of “Buy” and an average price target of $50.46.

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its position in Insulet Corporation by 0.5% in the second quarter. FMR LLC now owns 8,687,487 shares of the medical instruments supplier’s stock valued at $445,755,000 after buying an additional 39,836 shares during the period. Capital Research Global Investors boosted its position in Insulet Corporation by 2.5% in the second quarter. Capital Research Global Investors now owns 5,883,633 shares of the medical instruments supplier’s stock valued at $301,889,000 after buying an additional 145,724 shares during the period. Vanguard Group Inc. boosted its position in Insulet Corporation by 2.2% in the second quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock valued at $238,854,000 after buying an additional 98,272 shares during the period. BlackRock Inc. boosted its position in Insulet Corporation by 7,285.2% in the first quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock valued at $180,724,000 after buying an additional 4,137,326 shares during the period. Finally, Clearbridge Investments LLC boosted its position in Insulet Corporation by 64.2% in the first quarter. Clearbridge Investments LLC now owns 2,379,224 shares of the medical instruments supplier’s stock valued at $102,521,000 after buying an additional 930,062 shares during the period.

Insulet Corporation (NASDAQ:PODD) opened at 54.26 on Wednesday. The company’s market capitalization is $3.15 billion. Insulet Corporation has a 52 week low of $30.69 and a 52 week high of $55.46. The stock’s 50 day moving average price is $51.50 and its 200-day moving average price is $45.38.

ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/16/insulet-corporation-podd-expected-to-announce-quarterly-sales-of-114-24-million.html.

About Insulet Corporation

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet Corporation (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.